Cybin Inc. (OTCMKTS:CYBN - Get Free Report) traded up 3.9% on Thursday . The company traded as high as $8.68 and last traded at $8.58. 323,633 shares changed hands during trading, an increase of 13% from the average session volume of 285,177 shares. The stock had previously closed at $8.26.
Cybin Price Performance
The firm's fifty day moving average is $7.50 and its two-hundred day moving average is $8.11. The firm has a market cap of $187.65 million, a price-to-earnings ratio of -42.89 and a beta of 0.68.
About Cybin
(
Get Free Report)
Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.
Further Reading
Before you consider Cybin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cybin wasn't on the list.
While Cybin currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
